A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Phase 4

Terminated

• Conditions: Macular Degeneration

• Registration Number: NCT00312351
• Lead Sponsor: Eyetech Pharmaceuticals

Brief Summary

The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-04
• Study First Submitted: 2006-04-06
• Study First Submitted QC: 2006-04-07
• Study First Posted: 2006-04-10
• Study Completion: 2006-11
• Status Verified: 2007-01
• Last Update Submitted: 2007-01-12
• Last Update Posted: 2007-01-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 262

Inclusion Criteria

• Subjects of either gender, aged 50 years or greater.
• Subfoveal choroidal neovascularization (CNV) due to AMD.
• Best corrected visual acuity in the study eye between 20/40 and 20/320.
• Normal electroretinogram, and corneal endothelial cell density of 1500 cells/mm2 or more.

Exclusion Criteria

• Any prior photodynamic therapy (PDT) with Visudyne or thermal laser to the study eye.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Charlotte Eye, Ear, Nose and Throat Associates, P.A.; 🇺🇸 Charlotte, North Carolina, United States